评估用于胰腺β细胞质量成像的PET脑放射性配体:11C-(+)-PHNO的潜在应用价值
研究筛选脑放射性配体用于测量胰腺β细胞质量(BCM),12名健康对照和2名1型糖尿病(T1DM)受试者接受6种示踪剂的动态PET/CT。11C-(+)-PHNO是唯一在胰腺显示持续高摄取且对比度高的配体,健康对照平均SUV为13.8,C肽不可测的T1DM受试者SUV为4.0(降低71%),空腹C肽0.38 ng/mL者SUV为11.0(降低20%)。结论认为11C-(+)-PHNO是BCM的潜在标志物,需进一步研究确认D2/D3受体对β细胞的特异性。
要点
- 11C-(+)-PHNO在健康对照胰腺中20-30分钟平均SUV为13.8,明显高于腹部其他器官。
- C肽不可测的T1DM受试者胰腺SUV为4.0,较健康对照降低71%。
- 空腹C肽0.38 ng/mL的T1DM受试者胰腺SUV为11.0,较健康对照降低20%。
核心结论
- 11C-(+)-PHNO是胰腺β细胞质量的潜在标志物,其对D3受体的结合为D2受体的2倍。
- 需进一步体外和体内研究确立D2/D3受体对β细胞的特异性,以将11C-(+)-PHNO发展为临床测量健康对照和糖尿病受试者BCM的候选方法。
研究设计与样本
- 研究筛选脑放射性配体用于识别β细胞,检查β细胞基因图谱中的内分泌胰腺受体靶点并与本机构可用的脑放射性配体交叉对照。
- 12名健康对照受试者和2名T1DM受试者接受6种示踪剂的动态PET/CT扫描。
主要发现
- 基于前30分钟数据,11C-(+)-PHNO是唯一在胰腺显示持续摄取且与肾脏、肝脏和脾脏等腹部器官对比度高的放射性配体。
- 20至30分钟平均SUV显示健康对照中11C-(+)-PHNO高摄取(SUV为13.8),C肽不可测的T1DM受试者SUV为4.0(降低71%),空腹C肽0.38 ng/mL的T1DM受试者SUV为11.0(降低20%)。
- 胰腺外腹部器官的SUV在健康对照和T1DM受试者间未显示可测量差异。
- 在非人灵长类中使用D3和D2拮抗剂后,11C-PHNO的特异性胰腺结合(SUVR-1)分别降低57%和38%。
局限性
- 需进一步体外和体内研究确立D2/D3受体对β细胞的特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 1 diabetes mellitus (T1DM) is characterized by a loss of β-cells in the islets of Langerhans of the pancreas and subsequent deficient insulin secretion in response to hyperglycemia. Development of an in vivo test to measure β-cell mass (BCM) would greatly enhance the ability to track diabetes therapies. β-cells and neurologic tissues have common cellular receptors and transporters, therefore, we screened brain radioligands for their ability to identify β-cells. Methods: We examined a β-cell gene atlas for endocrine pancreas receptor targets and cross-referenced these targets with brain radioligands that were available at our institution. Twelve healthy control subjects and 2 T1DM subjects underwent dynamic PET/CT scans with 6 tracers. Results: The D2/D3 receptor agonist radioligand 11C-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) was the only radioligand to demonstrate sustained uptake in the pancreas with high contrast versus abdominal organs such as the kidneys, liver, and spleen, based on the first 30 min of data. Mean SUV from 20 to 30 min demonstrated high uptake of 11C-(+)-PHNO in healthy controls (SUV, 13.8) with a 71% reduction in a T1DM subject with undetectable levels of C-peptide (SUV, 4.0) and a 20% reduction in a T1DM subject with fasting C-peptide level of 0.38 ng/mL (SUV, 11.0). SUV in abdominal organs outside the pancreas did not show measurable differences between the control and T1DM subjects, suggesting that the changes in SUV of 11C-(+)-PHNO may be specific to changes in the pancreas between healthy controls and T1DM subjects. When D3 and D2 antagonists were used in nonhuman primates, specific pancreatic binding (SUVR-1) of 11C-PHNO was reduced by 57% and 38%, respectively. Conclusion:11C-(+)-PHNO is a potential marker of BCM, with 2:1 binding of D3 receptors over D2 receptors. Further in vitro and in vivo studies to establish D2/D3 receptor specificity to β-cells is warranted to characterize 11C-(+)-PHNO as a candidate for clinical measurement of BCM in healthy control and diabetic subjects.
引用
- Bini J, Naganawa M, Nabulsi N, et al. Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO. J Nucl Med. 2018. PMID: 29371405. doi:10.2967/jnumed.117.197285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。